Brazilian Journal of Pulmonology

ISSN (on-line): 1806-3756 | ISSN (printed): 1806-3713

SBPT

Publication continuous and bimonthly

SCImago Journal & Country Rank
Advanced Search

 

Current Issue: 2007 - Volume 33 - Number 4 (July/August)

EDITORIAL

Assessing the severity and prognosis of chronic obstructive pulmonary disease: is it still sufficient to measure FEV1 alone?

Avaliando a gravidade e o prognóstico da doença pulmonar obstrutiva crônica: a medida do VEF1 ainda é suficiente?

 

Irma de Godoy

 

 

 

Since Fletcher & Peto described the natural history of the decrease in forced expiratory volume in one second (FEV1) in postal and transport workers in London, progressive and irreversible airway obstruction has been the characteristic that defines chronic obstructive pulmonary disease (COPD).(1) The FEV1 is the basis of the current classification of disease severity. Increased FEV1 values and a lower rate of decrease in FEV1 are the outcome measures most commonly used in clinical research to evaluate the response to treatment and the prevention of COPD progression.(2) However, for the patient with COPD, whose complaint does not refer to the alterations in these functional variables, the most important outcome measures are the symptoms, especially the degree of dyspnea and exercise tolerance. Measurement of FEV1 does not usually provide information that allow the assessment of patient performance in activities of daily living, as well as having a weak correlation with the degree of dyspnea and exercise capacity, and has little application in the assessment of bronchodilator response.(3) All these findings, as well as the current concept that COPD presents significant extrapulmonary changes, suggest the need for new markers of disease severity, progression, and prognosis that make it possible to assess not only the functional repercussions, but also the influence of such repercussions on patient symptoms and limitations. Many studies have been carried out with these objectives, and new data have been obtained. Examples include the information that smoking cessation reduces the progression of the disease and that the decrease in the number of exacerbations, as well as their prevention, can change the rate of FEV1 decrease and improve patient quality of life.(2) The degree of exercise-related dyspnea - which is one of the basic symptoms in patients with COPD, appearing in the initial phase of the disease and affecting the activities of daily living - correlates more closely with five-year survival rates than does the classification of disease severity by FEV1 values.(4) The systemic manifestations of COPD, which include changes in quality of life and in body composition, as well as repercussions on exercise tolerance, also correlate with the frequency of exacerbations, with hospitalization rates, and with patient survival.(4) Studies indicate that weight loss, low body mass index (BMI), and low fat-free mass index are negative prognostic factors, regardless of disease severity, and are related to exercise capacity in patients with COPD.(2) The distance covered on the 6-minute walk test (6MWT), which reflects the functional capacity of patients with COPD, was also a better predictor of mortality than were other traditional markers of disease severity.(4) However, the identification of numerous markers associated with the prognosis and the systemic character of the disease indicate the need for studies on the influence of the combination of various parameters on the establishment of disease severity and prognosis. In this sense, an index that assesses the systemic and respiratory manifestations of COPD, and which could better characterize and predict outcomes in such patients, was created. This index was designated the Body mass index, airway Obstruction, Dyspnea, and Exercise capacity (BODE) index. The BODE index is a ten-point scale that combines the measurements of BMI, severity of airway obstruction, degree of dyspnea, and exercise capacity.(4)

An important characteristic of generalized airway obstruction is lung hyperinflation, which is defined as an increase in end-inspiratory volume.(3) This increase occurs at rest and becomes accentuated during exercise (dynamic hyperinflation) due to the increased ventilation and the airflow limitation. A simple method of assessing lung hyperinflation at rest and during exercise is to measure inspiratory capacity (IC), defined as the maximum amount of air that can be inhaled after expiratory rest, which typically corresponds to the functional residual capacity (FRC). This measurement was neglected for many years. However, it has recently been recognized as a reserve that allows an increase in tidal volume during periods of higher ventilatory demand and reflects the variations in end-inspiratory volume and in FRC, as long as total lung capacity (TLC) remains constant. Therefore, IC has been assessed and has proven useful as a predictive factor of exercise capacity in patients with COPD. In this issue of the Brazilian Journal of Pulmonology, Santos et al.(5) analyze how IC, expressed as a percentage of the value predicted for the Brazilian population,(5) correlates not only with other parameters of pulmonary function, but also with the sensation of dyspnea, the use of medications, and other prognostic markers, such as the distance covered on the 6MWT, the BODE index, and the classification of COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The authors observed that 59% of the variation in the distance covered on the 6MWT could be explained by the postbronchodilator IC (% of predicted), by the use of long-term oxygen therapy at home, and by the number of drugs used in treatment of the disease. Values of IC = 70% of predicted were more common in patients who were categorized as class 3 or 4 according to the BODE index and whose disease severity was categorized as 3 or 4 according to the GOLD criteria. These data reinforce the hypothesis, which has been tested in previous studies, that lung hyperinflation is present in patients with more severe disease and has an influence on exercise capacity. Other researchers have demonstrated that lung hyperinflation, expressed by the IC/TLC ratio, is an independent predictor of mortality in patients with COPD.(6) The authors evaluated the predictive power of the IC/TLC ratio and found that the cut-off point of 25% resulted in a sensitivity of 0.71, specificity of 0.69, positive predictive value of 0.46, and negative predictive value of 0.87. At this cut-off point, there were significant differences in mortality: 71% in the patients with an IC/TLC = 25% vs. 29% in those with an IC/TLC > 25%. One study conducted in Brazil also showed the influence of the postbronchodilator IC/TLC ratio on exercise capacity in patients with COPD.(7) The authors observed that IC/TLC values = 28% were related to severely decreased exercise capacity, and higher values were found in patients with lower impairment of functional capacity. Therefore, these two studies indicate that IC/TLC values can be used as prognostic indicators (= 0.25) or as indicators of reduced physical capacity (= 0.28). According to Santos et al.,(5) the measurement of TLC can only be performed in a limited number of medical centers across Brazil. Therefore, they propose that postbronchodilator IC values < 70% of predicted for the Brazilian population be used as a cut-off point.

In summary, the current knowledge indicates the need to perform longitudinal studies in order to determine how the various possible markers of COPD severity and prognosis, as well as the cut-off points proposed, reflect the disease progression in a given patient. In the meantime, taking into consideration the infrastructure available in the different health care facilities, we should use the markers that have proven valuable in determining outcomes that are important from a physiological point of view, complemented by those focused on the limitations of the patients. The FEV1 value and its change over time remain important markers of COPD. However, additional assessments are necessary to more accurately estimate the repercussions of the disease.

References

1. Wise RA. The value of forced expiratory volume in 1 second decline in the assessment of chronic obstructive pulmonary disease progression. Am J Med. 2006; 119(10 Suppl 1):S4-S11.

2. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease - 2006 update. Am J Respir Crit Care Med. 2007; [Epub ahead of print]

3. Cooper CB. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med. 2006;119(10 Suppl 1):S21-S31.

4. Tashkin DP. The role of patient-centered outcomes in defining the clinical course of chronic obstructive pulmonary disease. Introduction. Am J Med. 2006;119(10 Suppl 1):S1-S3.

5. Santos C, Pereira C, Viegas C. Capacidade inspiratória, limitação de exercício e preditores de gravidade e prognóstico em doença pulmonar obstrutiva crônica. J Bras Pneumol. 2007;33(4):389-96.

6. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005; 171(6):591-7.

7. Albuquerque AL, Nery LE, Villaça DS, Machado TY, Oliveira CC, Paes AT, et al. Inspiratory fraction and exercise impairment in COPD patients GOLD stages II-III. Eur Respir J. 2006;28(5):939-44.
______________________________________________________________________________________
Tenured professor in the Pulmonology Division of the Clinical Medicine Department of the Universidade Estadual Paulista - UNESP, Paulista State University. Botucatu School of Medicine, Botucatu,
Brazil.


 

 


The Brazilian Journal of Pulmonology is indexed in:

Latindex Lilacs SciELO PubMed ISI Scopus Copernicus pmc

Support

CNPq, Capes, Ministério da Educação, Ministério da Ciência e Tecnologia, Governo Federal, Brasil, País Rico é País sem Pobreza
Secretariat of the Brazilian Journal of Pulmonology
SCS Quadra 01, Bloco K, Salas 203/204 Ed. Denasa. CEP: 70.398-900 - Brasília - DF
Fone/fax: 0800 61 6218/ (55) (61) 3245 1030/ (55) (61) 3245 6218
E-mails: jbp@jbp.org.br
jpneumo@jornaldepneumologia.com.br

Copyright 2019 - Brazilian Thoracic Association

Logo GN1